Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach

Abstract

Purpose: Antitumor clinical activity has been demonstrated for the MDM2 antagonist RG7112, but patient tolerability for the necessary daily dosing was poor. Here, utilizing RG7388, a second-generation nutlin with superior selectivity and potency, we determine the feasibility of intermittent dosing to guide the selection of initial phase I scheduling regimens.Experimental Design: A pharmacokinetic-pharmacodynamic (PKPD) model was developed on the basis of preclinical data to determine alternative dosing schedule requirements for optimal RG7388-induced antitumor activity. This PKPD model was used to investigate the pharmacokinetics of RG7388 linked to the time-course of the antitumor effect in an osteosarcoma xenograft model in mice. These data were used to prospectively predict intermittent and continuous dosing regimens, resulting in tumor stasis in the same model system.Results: RG7388-induced apoptosis was delayed relative to drug exposure with continuous treatment not required. In initial efficacy testing, daily dosing at 30 mg/kg and twice a week dosing at 50 mg/kg of RG7388 were statistically equivalent in our tumor model. In addition, weekly dosing of 50 mg/kg was equivalent to 10 mg/kg given daily. The implementation of modeling and simulation on these data suggested several possible intermittent clinical dosing schedules. Further preclinical analyses confirmed these schedules as viable options.Conclusion: Besides chronic administration, antitumor activity can be achieved with intermittent schedules of RG7388, as predicted through modeling and simulation. These alternative regimens may potentially ameliorate tolerability issues seen with chronic administration of RG7112, while providing clinical benefit. Thus, both weekly (qw) and daily for five days (5 d on/23 off, qd) schedules were selected for RG7388 clinical testing.

Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist

“…To this end, Higgins et al have proposed a modeling approach for strategic scheduling of MDM2 PPI inhibitors. 16 …”

Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations

“…Human PK was predicted by a PBPK model and linked to the scaled thrombocytopenia model to predict the time‐course of drug‐induced thrombocytopenia in humans . Simulations suggested dosing regimens projected to provide similar anticancer effect based on a semimechanistic PK‐PD model developed to predict tumor growth inhibition in tumor‐bearing xenograft mice . The most favorable dosing regimen that allowed differentiation of antitumor effect from drug‐induced thrombocytopenia was selected and implemented in the FIH trial.…”

Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma

“…Animals were monitored 2–3 times weekly and euthanized humanely just before showing signs of illness/suffering such as abdominal dilatation, paraplegia, dehydration, or severe weight loss. Percentage increase in lifespan (%ILS) was calculated based on both median and mean survival to humane endpoint, as previously described . For more detailed procedures see Supporting Information.…”

“…Idasanutlin (RO5503781/RG7388), a pyrrolidine and second generation MDM2 antagonist from Hoffman‐La Roche has enhanced potency, selectivity and bioavailability, and has been developed in both oral and intravenous (IV; RO6839921) formulations . To overcome tolerability issues with daily administration, intermittent schedules of idasanutlin, designed to enable bone marrow recovery, are being clinically evaluated in adult cancers both alone and in combination …”